Clinical Trial Update: A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of navitoclax as monotherapy and in combination w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Drugs mentioned

• Navitoclax (navitoclax)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: AbbVie | Conditions: Myeloproliferative Neoplasm | Phase 1 | Status: ACTIVE_NOT_RECRUITING